LBA89 A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer

Lin, Yani; Qin, S.; Zy, Li; Yang, Han Kwang; Fu, Wei; Sh, LI; Wx, Chen; Zr, Gao; Miao, W-B.; Xu, H-Q.; Zhang, Q.; Zhao, Xiwa; Bao, J-D.; Li, LF; Ren, Yongcheng; Lin, Chang-Ping; Jing, S.; Ma, Q-J.; Liang, Jintai; Chen, G.

doi:10.1016/j.annonc.2020.08.2333

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These first results led to a randomized, double-blind, multicenter phase 3 trial that aimed to evaluate the efficacy and safety of apatinib in 92 patients with RAI-refractory DTC (NCT03048877). The results of the study were recently presented at ESMO meeting 2020 by Lin et al [ 115 ] and they confirmed the efficacy and safety of this drug. Forty-six patients were randomized to apatinib arm and 46 to placebo arm.…”

Section: Drugs Under Evaluationsupporting

confidence: 74%

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

Lorusso

Cappagli

Valerio

et al. 2021

IJMS

View full text Add to dashboard Cite

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst prognosis is for anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC). Whenever a local or metastatic advanced disease is present, other treatments are required, varying from local to systemic therapies. In the last decade, the efficacy of the targeted therapies and, in particular, tyrosine kinase inhibitors (TKIs) has been demonstrated. They can prolong the disease progression-free survival and represent the most important therapeutic option for the treatment of advanced and progressive thyroid cancer. Currently, lenvatinib and sorafenib are the approved drugs for the treatment of RAI-refractory DTC and PDTC while advanced MTC can be treated with either cabozantinib or vandetanib. Dabrafenib plus trametinib is the only approved treatment by FDA for BRAFV600E mutated ATC. A new generation of TKIs, specifically for single altered oncogenes, is under evaluation in phase 2 and 3 clinical trials. The aim of this review was to provide an overview of the current and future treatments of thyroid cancer with regards to the advanced and progressive cases that require systemic therapies that are becoming more and more targeted on the molecular identity of the tumor.

show abstract

Section: Drugs Under Evaluationsupporting

confidence: 74%

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

Lorusso

Cappagli

Valerio

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Sorafenib and Lanvatinib, a multitarget TKI, have demonstrated a major improvement in progression-free survival in phase III clinical trials [ 72 , 73 ]. Several other drugs are under investigation in clinical trials, with some of the most promising results coming from apatinib, an inhibitor of VEGFR [ 74 ], and from TKI treatments in thyroid cancer with rarer fusion mutations such as larotectinib in TRK mutate tumors in basket trials [ 75 ]. Nevertheless, with these latest drug types, there is increasing evidence of the possibility to re-differentiate RAI-R cancers through molecular blockage induced by targeted drug direct effect [ 76 ].…”

Section: Advanced and Radioactive Iodine Refractory Cancermentioning

confidence: 99%

Molecular Imaging and Theragnostics of Thyroid Cancers

Giovanella

Deandreis

Vrachims³

et al. 2022

Cancers

View full text Add to dashboard Cite

Molecular imaging plays an important role in the evaluation and management of different thyroid cancer histotypes. The existing risk stratification models can be refined, by incorporation of tumor-specific molecular markers that have theranostic power, to optimize patient-specific (individualized) treatment decisions. Molecular imaging with varying radioisotopes of iodine (i.e., 131I, 123I, 124I) is an indispensable component of dynamic and theragnostic risk stratification of differentiated carcinoma (DTC) while [18F]F-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) helps in addressing disease aggressiveness, detects distant metastases, and risk-stratifies patients with radioiodine-refractory DTC, poorly differentiated and anaplastic thyroid cancers. For medullary thyroid cancer (MTC), a neuroendocrine tumor derived from thyroid C-cells, [18F]F-dihydroxyphenylalanine (6-[18F]FDOPA) PET/CT and/or [18F]FDG PET/CT can be used dependent on serum markers levels and kinetics. In addition to radioiodine therapy for DTC, some theragnostic approaches are promising for metastatic MTC as well. Moreover, new redifferentiation strategies are now available to restore uptake in radioiodine-refractory DTC while new theragnostic approaches showed promising preliminary results for advanced and aggressive forms of follicular-cell derived thyroid cancers (i.e., peptide receptor radiotherapy). In order to help clinicians put the role of molecular imaging into perspective, the appropriate role and emerging opportunities for molecular imaging and theragnostics in thyroid cancer are discussed in our present review.

show abstract

Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer

Leboulleux

Lamartina

Hadoux

et al. 2022

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

LBA89 A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer

Cited by 3 publications

References 0 publications

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

Molecular Imaging and Theragnostics of Thyroid Cancers

Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer

Contact Info

Product

Resources

About